Skip to main content
Top
Published in: Archives of Orthopaedic and Trauma Surgery 3/2008

01-03-2008 | Basic Science

The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model

Authors: Bruce E. Rapuano, Roosevelt Boursiquot, Emre Tomin, Daniel E. MacDonald, Surekha Maddula, Deepak Raghavan, Joseph M. Lane, David L. Helfet

Published in: Archives of Orthopaedic and Trauma Surgery | Issue 3/2008

Login to get access

Abstract

Introduction

Traumatic heterotopic ossification (HO) is a common clinical condition associated with various orthopedic procedures that involve injury to soft tissues near bone. In this study, we tested the hypothesis that the prophylactic effects of NSAID’s in the treatment of HO are mediated via inhibition of the COX-2 enzyme. Here we describe a rat model that simulates HO in the human that was used to test the above hypothesis.

Materials and methods

Heterotopic ossification was surgically induced in the quadriceps by injury to the muscle and femoral periosteum and transplantation of donor bone marrow cells containing osteoprogenitors into the site of injury. HO was imaged and quantified by micro-CT scanning of femurs removed from sacrificed animals at 6 weeks post-injury, three-dimensional computer reconstructions of the scanned bones and computer-assisted morphometric analysis. Prostaglandin E2 (PGE2) synthesis was quantified using an enzyme immunoassay system. The effects of a nonselective COX inhibitor or specific inhibitors of COX-1 or COX-2 following oral administration on the content of ectopic bone and PGE2 were also measured.

Results

Micro-CT and histological analyses demonstrated that all of the femurs in operated limbs developed HO in the vastus lateralis muscle belly of the quadriceps close to the anterior femur. Only the COX-1,2 nonselective and COX-2 inhibitors significantly decreased HO formation (by about one-third in each case; P < 0.05). PGE2 synthesis at the site of injury was increased 50- and 100-fold (to 25 ng/g tissue) within 1 and 7 days, respectively, post-injury with the levels declining to near baseline within 2 weeks of surgery. Both the COX-1,2 nonselective and COX-2 inhibitors significantly decreased PGE2 levels to 25% of control HO levels within 24 h of the first administration, even at low dosages. The COX-1 inhibitor only produced the same effect after 1 week of administration.

Conclusion

These findings suggest that although inhibitors of COX-2 or COX-1 reduced PGE2 synthesis, only the COX-2 enzyme plays a role in the mechanism of traumatic HO.
Literature
1.
go back to reference Ahrengart L, Blomgren G, Tornkvist H (1994) Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 65:139–141PubMed Ahrengart L, Blomgren G, Tornkvist H (1994) Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 65:139–141PubMed
2.
go back to reference Anderson HC (1976) Osteogenetic epithelial–esenchymal cell interactions. Clin Orthop 119:211–223PubMed Anderson HC (1976) Osteogenetic epithelial–esenchymal cell interactions. Clin Orthop 119:211–223PubMed
3.
go back to reference Anderson HC, Merker PC, Foch J (1964) Formation of tumors containing bone after intramuscular injection of transformed human amnion cells (Fl) into cortisone-treated mice. Am J Pathol 44:507–519PubMed Anderson HC, Merker PC, Foch J (1964) Formation of tumors containing bone after intramuscular injection of transformed human amnion cells (Fl) into cortisone-treated mice. Am J Pathol 44:507–519PubMed
4.
go back to reference Bartlett CS, Rapuano BE, Lorich DG Wu T, Hsu JF, Lane JM, Helfet DL (2006) Early changes in prostaglandins precede bone formation in a rabbit model of heterotopic ossification. Bone 38:322–332PubMedCrossRef Bartlett CS, Rapuano BE, Lorich DG Wu T, Hsu JF, Lane JM, Helfet DL (2006) Early changes in prostaglandins precede bone formation in a rabbit model of heterotopic ossification. Bone 38:322–332PubMedCrossRef
5.
go back to reference Bauer FC, Nilsson OS, Tornkvist H (1984) Formation and resorption of bone induced by demineralized bone matrix implants in rats. Clin Orthop 191:139–143PubMed Bauer FC, Nilsson OS, Tornkvist H (1984) Formation and resorption of bone induced by demineralized bone matrix implants in rats. Clin Orthop 191:139–143PubMed
6.
go back to reference Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095–1105PubMedCrossRef Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095–1105PubMedCrossRef
7.
go back to reference Borens O, Rapuano BE, Tomin A, Lane JM, Helfet DL (2004) The effect of COX-2 inhibitors on the formation of heterotopic bone in a new rat model. J Bone Joint Surg 86-B(suppl III):259. (Privileged communication) Borens O, Rapuano BE, Tomin A, Lane JM, Helfet DL (2004) The effect of COX-2 inhibitors on the formation of heterotopic bone in a new rat model. J Bone Joint Surg 86-B(suppl III):259. (Privileged communication)
8.
go back to reference Bosse MJ, Poka A, Reinert CM, Ellwanger F, Slawson R, McDevitt ER (1988) Heterotopic ossification as a complication of acetabular fracture. Prophylaxis with low-dose irradiation. J Bone Joint Surg Am 70:1231–1237PubMed Bosse MJ, Poka A, Reinert CM, Ellwanger F, Slawson R, McDevitt ER (1988) Heterotopic ossification as a complication of acetabular fracture. Prophylaxis with low-dose irradiation. J Bone Joint Surg Am 70:1231–1237PubMed
9.
go back to reference Bostrom MP, Lane JM, Berberian WS, Missri AA, Tomin E, Weiland A, Doty SB, Glaser D, Rosen VM (1995) Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res 13:357–367PubMedCrossRef Bostrom MP, Lane JM, Berberian WS, Missri AA, Tomin E, Weiland A, Doty SB, Glaser D, Rosen VM (1995) Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res 13:357–367PubMedCrossRef
11.
12.
go back to reference Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr (1973) Ectopic ossification following total hip replacement: Incidence and a method of classification. J Bone Joint Surg 55-A:1629–1632 Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr (1973) Ectopic ossification following total hip replacement: Incidence and a method of classification. J Bone Joint Surg 55-A:1629–1632
13.
go back to reference Cella JP, Salvati EA, Sculco TP (1988) Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 3:229–234PubMed Cella JP, Salvati EA, Sculco TP (1988) Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 3:229–234PubMed
14.
go back to reference Chantraine A, Minaire P (1981) Para-osteo-arthropathies: a new theory and mode of treatment. Scand J Rehabil Med 13:31–37PubMed Chantraine A, Minaire P (1981) Para-osteo-arthropathies: a new theory and mode of treatment. Scand J Rehabil Med 13:31–37PubMed
15.
go back to reference Charnley J (1972) The long term results of low-friction arthroplasty of the hip performed as primary intervention. J Bone Joint Surg [Br] 54:61–76 Charnley J (1972) The long term results of low-friction arthroplasty of the hip performed as primary intervention. J Bone Joint Surg [Br] 54:61–76
16.
go back to reference Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS, Adams DJ, Xu M, Hoshi K, Katavic V, Herschman HR, Raisz LG, Pilbeam CC (2002) Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 17:1430–1440PubMedCrossRef Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS, Adams DJ, Xu M, Hoshi K, Katavic V, Herschman HR, Raisz LG, Pilbeam CC (2002) Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 17:1430–1440PubMedCrossRef
17.
go back to reference Collins M, Stone M, Harkess JW, Bliven FE (1965) Experimental myositis ossificans in dogs. J Bone Joint Surg Am 47:1277 Collins M, Stone M, Harkess JW, Bliven FE (1965) Experimental myositis ossificans in dogs. J Bone Joint Surg Am 47:1277
18.
go back to reference Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase inhibition: evidence from animal models of inflammation. BioDrugs 15:1–9PubMedCrossRef Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase inhibition: evidence from animal models of inflammation. BioDrugs 15:1–9PubMedCrossRef
19.
go back to reference Dannhardt G, Kiefer W (2001) Cyclooxygenase inhibitors—current status and future prospects. Eur J Med Chem 36:109–126PubMedCrossRef Dannhardt G, Kiefer W (2001) Cyclooxygenase inhibitors—current status and future prospects. Eur J Med Chem 36:109–126PubMedCrossRef
20.
go back to reference Daum WJ, Scarborough MT, Gordon W Jr, Uchida T (1992) Heterotopic ossification and other perioperative complications of acetabular fractures. J Orthop Trauma 6:427–432PubMedCrossRef Daum WJ, Scarborough MT, Gordon W Jr, Uchida T (1992) Heterotopic ossification and other perioperative complications of acetabular fractures. J Orthop Trauma 6:427–432PubMedCrossRef
21.
go back to reference Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M (1989) The direct examination of three-dimensional bone architecture in vitro by computed tomography. J Bone Miner Res 4:3–11PubMedCrossRef Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M (1989) The direct examination of three-dimensional bone architecture in vitro by computed tomography. J Bone Miner Res 4:3–11PubMedCrossRef
22.
go back to reference Fort J (1999) Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop 28:13–18PubMed Fort J (1999) Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop 28:13–18PubMed
23.
go back to reference Foster DE, Hunter JR (1987) The direct lateral approach to the hip for arthroplasty. Advantages and complications. Orthopedics 10:274PubMed Foster DE, Hunter JR (1987) The direct lateral approach to the hip for arthroplasty. Advantages and complications. Orthopedics 10:274PubMed
24.
go back to reference Fritton JC, Myers ER, Wright TM, van der Meulen MCH (2005) Loading induces site-specific increases in mineral content assessed by microcomputed tomography of the mouse tibia. Bone 36:1030–1038PubMedCrossRef Fritton JC, Myers ER, Wright TM, van der Meulen MCH (2005) Loading induces site-specific increases in mineral content assessed by microcomputed tomography of the mouse tibia. Bone 36:1030–1038PubMedCrossRef
25.
go back to reference Garland DE (1991) A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop 263:13–29PubMed Garland DE (1991) A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop 263:13–29PubMed
26.
go back to reference Gately S, Kerbel R (2003) Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:179–192PubMed Gately S, Kerbel R (2003) Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:179–192PubMed
27.
go back to reference Gebuhr P, Soelberg M, Orsnes T, Wilbek H (1991) Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand 62:226–229PubMedCrossRef Gebuhr P, Soelberg M, Orsnes T, Wilbek H (1991) Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand 62:226–229PubMedCrossRef
28.
go back to reference Geis GS (1999) Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 26(suppl 56):31–36 Geis GS (1999) Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 26(suppl 56):31–36
29.
30.
go back to reference Jacquemin C (2000) Biological functions of cyclooxygenase 2: control of its expression and activity. J Soc Biol 194:189–193PubMed Jacquemin C (2000) Biological functions of cyclooxygenase 2: control of its expression and activity. J Soc Biol 194:189–193PubMed
31.
go back to reference Jee WSS, Ma YF, Li M et al (1994) Sex steroids and prostaglandins in bone metabolism. In: Sex steroids and bone. Ernst Schering Research Foundation Workshop 9. Springer, Heidelberg, p 119 Jee WSS, Ma YF, Li M et al (1994) Sex steroids and prostaglandins in bone metabolism. In: Sex steroids and bone. Ernst Schering Research Foundation Workshop 9. Springer, Heidelberg, p 119
32.
go back to reference Jorgensen SM, Demirkaya O, Ritman EL (1998) Three-dimensional imaging of vasculature and parenchyma in intact rodent organs with X-ray micro-CT. Am J Physiol 275:H1103–H1114PubMed Jorgensen SM, Demirkaya O, Ritman EL (1998) Three-dimensional imaging of vasculature and parenchyma in intact rodent organs with X-ray micro-CT. Am J Physiol 275:H1103–H1114PubMed
33.
go back to reference Kim JH, Chu FC, Woodard HQ, Melamed MR, Huvos A, Cantin J (1978) Radiation-induced soft-tissue and bone sarcoma. Radiology 129:501–508PubMed Kim JH, Chu FC, Woodard HQ, Melamed MR, Huvos A, Cantin J (1978) Radiation-induced soft-tissue and bone sarcoma. Radiology 129:501–508PubMed
34.
go back to reference Kjaersgaard-Andersen P, Ritter MA (1992) Short-term treatment with nonsteroidal antiinflammatory medications to prevent heterotopic bone formation after total hip arthroplasty. A preliminary report Clin Orthop 279:157–162PubMed Kjaersgaard-Andersen P, Ritter MA (1992) Short-term treatment with nonsteroidal antiinflammatory medications to prevent heterotopic bone formation after total hip arthroplasty. A preliminary report Clin Orthop 279:157–162PubMed
35.
go back to reference Lane NE (1997) Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 24(suppl 49):20–24 Lane NE (1997) Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 24(suppl 49):20–24
36.
go back to reference Lipsky PE, Isakson PC (1997) Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 24(suppl 49):9–14 Lipsky PE, Isakson PC (1997) Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 24(suppl 49):9–14
37.
go back to reference Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, Lopez-Munoz FJ (2002) Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol 54:405–412PubMedCrossRef Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, Lopez-Munoz FJ (2002) Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol 54:405–412PubMedCrossRef
38.
go back to reference McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272–277PubMedCrossRef McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272–277PubMedCrossRef
39.
go back to reference Michelsson J-E, Pettila M, Valtakari T, Leivo I, Aho HJ (1994) Isolation of bone from muscles prevents the development of experimental callus-like heterotopic bone. Clin Orthop Relat Res 302:266–272PubMed Michelsson J-E, Pettila M, Valtakari T, Leivo I, Aho HJ (1994) Isolation of bone from muscles prevents the development of experimental callus-like heterotopic bone. Clin Orthop Relat Res 302:266–272PubMed
40.
go back to reference Miller SC, Marks SC Jr (1993) Local stimulation of new bone formation by prostaglandin E1: quantitative histomorphometry and comparison of delivery by minipumps and controlled release pellets. Bone 14:143PubMedCrossRef Miller SC, Marks SC Jr (1993) Local stimulation of new bone formation by prostaglandin E1: quantitative histomorphometry and comparison of delivery by minipumps and controlled release pellets. Bone 14:143PubMedCrossRef
41.
go back to reference Moed BR, Karges DE (1994a) Prophylactic indomethacin for the prevention of heterotopic ossification after acetabular fracture surgery in high-risk patients. J Orthop Trauma 8:34–39PubMedCrossRef Moed BR, Karges DE (1994a) Prophylactic indomethacin for the prevention of heterotopic ossification after acetabular fracture surgery in high-risk patients. J Orthop Trauma 8:34–39PubMedCrossRef
42.
go back to reference Moed BR, Letournel E (1994b) Low dose irradiation and indomethacin prevent heterotopic ossification after acetabular fracture surgery. J Bone J Surg Br. 76:895–900 Moed BR, Letournel E (1994b) Low dose irradiation and indomethacin prevent heterotopic ossification after acetabular fracture surgery. J Bone J Surg Br. 76:895–900
43.
go back to reference Murat N, Hocaoglu N, Karatosun V, Yorukoglu K, Gidener S, Gunal I (2005) The effects of non-selective and cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats. Med Sci Monit 11:BR449–BR451PubMed Murat N, Hocaoglu N, Karatosun V, Yorukoglu K, Gidener S, Gunal I (2005) The effects of non-selective and cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats. Med Sci Monit 11:BR449–BR451PubMed
44.
go back to reference O’Connor JP (1998) Animal models of heterotopic ossification. Clin Orthop Rel Res 346:71–80 O’Connor JP (1998) Animal models of heterotopic ossification. Clin Orthop Rel Res 346:71–80
45.
go back to reference Okada Y et al (2000) Effects of cyclooxygenase-2 gene disruption on osteoblastic function. J Bone Miner Res 15(suppl):217 Okada Y et al (2000) Effects of cyclooxygenase-2 gene disruption on osteoblastic function. J Bone Miner Res 15(suppl):217
46.
go back to reference Oviedo JA, Wolfe MM (2001) Clinical potential of cyclo-oxygenase-2 inhibitors. BioDrugs 15:563–572PubMedCrossRef Oviedo JA, Wolfe MM (2001) Clinical potential of cyclo-oxygenase-2 inhibitors. BioDrugs 15:563–572PubMedCrossRef
47.
go back to reference Ozeki N, Lim M, Yao CC, Tolar M, Kramer RH (2006) Alpha7 integrin expressing human fetal myogenic progenitors have stem cell-like properties and are capable of osteogenic differentiation. Exp Cell Res 312:4162–4180PubMedCrossRef Ozeki N, Lim M, Yao CC, Tolar M, Kramer RH (2006) Alpha7 integrin expressing human fetal myogenic progenitors have stem cell-like properties and are capable of osteogenic differentiation. Exp Cell Res 312:4162–4180PubMedCrossRef
48.
go back to reference Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH (2000) Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase: mediation through different signaling pathways. J Biol Chem 275:28173–28179PubMed Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH (2000) Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase: mediation through different signaling pathways. J Biol Chem 275:28173–28179PubMed
49.
go back to reference Penning TD, Talley JJ, Bertenshaw SR et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase inhibitors: identification of 4-[-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347–1365PubMedCrossRef Penning TD, Talley JJ, Bertenshaw SR et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase inhibitors: identification of 4-[-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347–1365PubMedCrossRef
50.
go back to reference Powell WS (1980) Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 20:947–957PubMedCrossRef Powell WS (1980) Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 20:947–957PubMedCrossRef
51.
go back to reference Romano CL, Duci D, Romano D, Mazza M, Meani E (2004) Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 19:14–18PubMedCrossRef Romano CL, Duci D, Romano D, Mazza M, Meani E (2004) Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 19:14–18PubMedCrossRef
52.
go back to reference Sanghi S, MacLaughlin EJ, Jewell CW, Chaffer S, Naus PJ, Watson LE, Dostal DE (2006) Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 6:85–100PubMed Sanghi S, MacLaughlin EJ, Jewell CW, Chaffer S, Naus PJ, Watson LE, Dostal DE (2006) Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 6:85–100PubMed
53.
go back to reference Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, Kristensen SS, Pedersen P, Nielsen JB (1988) The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am 77:834–838 Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, Kristensen SS, Pedersen P, Nielsen JB (1988) The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am 77:834–838
54.
go back to reference Schneider DJ, Moulton MJ, Singapuri K, Chinchilli V, Deol GS, Krenitsky G, Pellegrini VD Jr (1998) The Frank Stinchfield Award. Inhibition of heterotopic ossification with radiation therapy in an animal model. Clin Orthop 355:35–46PubMedCrossRef Schneider DJ, Moulton MJ, Singapuri K, Chinchilli V, Deol GS, Krenitsky G, Pellegrini VD Jr (1998) The Frank Stinchfield Award. Inhibition of heterotopic ossification with radiation therapy in an animal model. Clin Orthop 355:35–46PubMedCrossRef
55.
go back to reference Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602PubMedCrossRef Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602PubMedCrossRef
56.
go back to reference Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313–13318PubMedCrossRef Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313–13318PubMedCrossRef
57.
go back to reference Studynkova JT, Kuchen S, Jeisy F, Schedel J, Charvat F, Jarosova K, Sprott H, Matucci-Cerinic M, Michel BA, Pavelka K, Vencovsky J, Gay S (2004) The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. Clin Exp Rheumatol 22:395–402PubMed Studynkova JT, Kuchen S, Jeisy F, Schedel J, Charvat F, Jarosova K, Sprott H, Matucci-Cerinic M, Michel BA, Pavelka K, Vencovsky J, Gay S (2004) The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. Clin Exp Rheumatol 22:395–402PubMed
58.
go back to reference Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790–804PubMedCrossRef Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790–804PubMedCrossRef
59.
go back to reference Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96:5292–5297PubMedCrossRef Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96:5292–5297PubMedCrossRef
60.
go back to reference Yokota K, Kusaka M, Oshima T, Yamamoto S, Kurihara N, Yoshino T, Kumegawa M (1986) Stimulation of prostaglandin E2 synthesis in cloned osteoblastic cells of mouse (MC3T3-E1) by epidermal growth factor. J Biol Chem 261:15410–15415PubMed Yokota K, Kusaka M, Oshima T, Yamamoto S, Kurihara N, Yoshino T, Kumegawa M (1986) Stimulation of prostaglandin E2 synthesis in cloned osteoblastic cells of mouse (MC3T3-E1) by epidermal growth factor. J Biol Chem 261:15410–15415PubMed
61.
go back to reference Yuan CJ, Mandal AK, Zhang Z, Mukherjee AB (2000) Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of non-steroidal anti-inflammatory drugs. Cancer Res 60:1084–1091PubMed Yuan CJ, Mandal AK, Zhang Z, Mukherjee AB (2000) Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of non-steroidal anti-inflammatory drugs. Cancer Res 60:1084–1091PubMed
62.
go back to reference Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O’Keefe RJ (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405–1415PubMedCrossRef Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O’Keefe RJ (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405–1415PubMedCrossRef
63.
go back to reference Arikawa T, Omura K, Morita I (2004) Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 200:400–406PubMedCrossRef Arikawa T, Omura K, Morita I (2004) Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 200:400–406PubMedCrossRef
64.
go back to reference Paralkar VM et al (2002) Regulation of BMP-7 expression by retinolic acid and prostaglandin E(2). J Cell Physiol 190:207–217PubMedCrossRef Paralkar VM et al (2002) Regulation of BMP-7 expression by retinolic acid and prostaglandin E(2). J Cell Physiol 190:207–217PubMedCrossRef
Metadata
Title
The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model
Authors
Bruce E. Rapuano
Roosevelt Boursiquot
Emre Tomin
Daniel E. MacDonald
Surekha Maddula
Deepak Raghavan
Joseph M. Lane
David L. Helfet
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Archives of Orthopaedic and Trauma Surgery / Issue 3/2008
Print ISSN: 0936-8051
Electronic ISSN: 1434-3916
DOI
https://doi.org/10.1007/s00402-007-0436-2

Other articles of this Issue 3/2008

Archives of Orthopaedic and Trauma Surgery 3/2008 Go to the issue